This company's payouts look safe.
Amgen's market-beating ways are unlikely to evaporate any time soon.
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END
Can Amgen be a market-beating stock?
/Gilead%20Sciences%2C%20Inc_%20pills-by%20%20Marc%20Bruxelle%20via%20Shutterstock.jpg)
Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20pharmaceuticals%20by-%20okskaz%20via%20iStock.jpg)
Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.
/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen has outperformed the S&P 500, and analysts remain optimistic about the stock’s prospects because of the positive Phase 2 clinical trial data of its obesity drug MariTide.
Find out if the high-flying biotech stock can keep on climbing higher.
/Abbvie%20Inc%20logo%20and%20meds-%20by%20Ascannio%20via%20Shutterstock.jpg)
Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains...